What's Happening?
A study published in JAMA Internal Medicine indicates that menopausal hormone therapy (MHT) can reduce the risk of cardiovascular disease (CVD) among perimenopausal or recently postmenopausal women experiencing vasomotor symptoms (VMS), such as hot flashes
and night sweats. The research, which analyzed data from the Study of Women’s Health Across the Nation (SWAN) over a median of 20 years, found that women who initiated MHT had a 22% lower risk for a CVD event. This protective effect was particularly evident when MHT was started within 6 to 10 years of menopause. The study also noted a significant variation in effect by race and ethnicity, with Black women showing a notably lower CVD event risk with MHT compared to White women or women of other races.
Why It's Important?
These findings are significant for women's health in the U.S., particularly given that up to 80% of women experience VMS during perimenopause and early postmenopause. While MHT is not currently recommended for CVD prevention, this study suggests a potential benefit for a specific demographic: midlife women with VMS who initiate therapy within a certain timeframe. The observed racial disparity in MHT's effect on CVD risk highlights the need for more nuanced, individualized treatment approaches and further research into how MHT impacts different populations. This information could influence future clinical guidelines, potentially leading to more tailored recommendations for MHT use, especially for women at higher risk of CVD or from underrepresented racial groups.
What's Next?
Despite the promising results, the study authors caution against drawing definitive clinical recommendations from observational data and emphasize that MHT is not currently recommended for CVD prevention. Future research will likely focus on conducting randomized controlled trials to confirm these findings and better understand the mechanisms behind MHT's cardiovascular benefits, particularly across diverse racial and ethnic groups. Clinicians may begin to consider the timing of MHT initiation and individual patient characteristics, including race and VMS severity, more carefully when discussing treatment options. This could lead to more personalized menopause care strategies, balancing symptom relief with long-term health outcomes, including cardiovascular health.
Beyond the Headlines
This study contributes to the ongoing re-evaluation of menopausal hormone therapy, moving beyond the broad concerns raised by earlier research like the Women's Health Initiative. It underscores the complexity of hormone therapy and the importance of considering individual factors such as age, time since menopause, and racial background. The finding that MHT's impact on CVD risk varies by race and ethnicity points to deeper biological or socioeconomic factors that influence health outcomes, necessitating a more inclusive approach to medical research. This nuanced understanding could help dismantle previous generalizations about MHT, empowering women and their healthcare providers to make more informed decisions based on personalized risk-benefit assessments, ultimately improving long-term health for menopausal women.
